Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $169.99 and last traded at $168.94, with a volume of 1944611 shares traded. The stock had previously closed at $169.10.
Analysts Set New Price Targets
A number of equities analysts have recently commented on JNJ shares. Bank of America raised their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday. UBS Group reiterated a "buy" rating and set a $190.00 target price (up previously from $180.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Guggenheim increased their target price on shares of Johnson & Johnson from $164.00 to $167.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.
View Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Stock Up 0.3%
The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a market cap of $408.11 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 2.14 and a beta of 0.41. The firm's 50-day simple moving average is $155.34 and its two-hundred day simple moving average is $155.45.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 EPS. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.07%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.
Institutional Investors Weigh In On Johnson & Johnson
Several institutional investors have recently modified their holdings of JNJ. Lantz Financial LLC boosted its stake in Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after acquiring an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new position in Johnson & Johnson during the 4th quarter worth approximately $453,000. Joel Isaacson & Co. LLC boosted its stake in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after acquiring an additional 2,526 shares during the last quarter. State of Wyoming boosted its stake in Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after acquiring an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC boosted its stake in Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after acquiring an additional 2,529 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
